Together, the public handed the Conservatives and Liberal Democrats an overall majority which they are using to press ahead
with their austerity drive.
Not exact matches
It also mentioned that governments might be inclined to organise referenda to counteract the «perception that the EU is an «elite -
driven» project,» as it notes that notion has been lingering since the start of the recession as «voters increasingly associat [e] the EU project
with austerity, rather than a source of union and prosperity.»
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®;
austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations
with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases
driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination
with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed
with the U.S. Securities and Exchange Commission (the SEC).
Up until 2012, Chinese drinkers had been devouring Australian wine, but Beijing's anti-corruption
drive, along
with a broader
austerity program, has smashed demand for luxury goods, from wine to Ferraris, and pinched local wine exports to the region.
Spending cuts caused by the coalition's
austerity drive are
driving down ministers» ability to deal
with this problem.
Those who had previously called for sweeping cuts have watched on
with dismay, bitterly aware that most governments struggle to extend the political will for
austerity drives beyond their first two years.
The government is preparing for a pitched battle
with unions, who have declared a campaign of co-ordinated industrial action in opposition to the
austerity drive.
The Conservatives have put all their hopes in the current
austerity drive, gambling it will preserve our triple AAA rating
with the credit agencies and get us growing again.
With the general election just over a year away, Labour has sought to focus attention on how strongly inflation has outstripped pay growth, adding to the burden on households from the coalition's
austerity drive.
In 2012 Reeves urged the Liberal Democrats to choose to become a radical centrist political party, «a hard -
driving radical liberal party of the political centre», continuing his campaign for centre left Liberal Democrats to leave, «Any attempt to position the Liberal Democrats as a party of the centre left after five years of
austerity government in partnership
with the Conservatives will be laughed out of court by the voters — and rightly so.
It suggests three major changes: 1) project and policy preparation need to reflect higher risks, where vulnerability assessments and greater use of climate scenario modelling are combined
with a better understanding of interconnections between smallholder farming and wider landscapes; 2) this deeper appreciation of interconnected risks should
drive a major scaling up of successful «multiple - benefit» approaches to sustainable agricultural intensification by smallholder farmers; 3) climate change and fiscal
austerity are reshaping the architecture of public international development finance.
The criminal justice recommendation, thus, fits within a wider narrative of concern at the Government's obsession
with digitalisation as a cost - saving,
austerity -
driven measure.